Everywhere Care for COVID-19 Diagnostics

article image

Sherlock and binx are teaming up to develop a rapid molecular test for SARS-CoV-2 that can be used in point-of-care settings to produce results in approximately 20 minutes or less.

While Sherlock Biosciences and binx health inc. are not the first to throw their hats into the high-stakes, frustrating, rapid testing ring, they certainly come to the table with credible track records, top management teams, and a few FDA wins.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: